Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

Joy C. Yang, Lanfang Bai, Stanley Yap, Allen C. Gao, Hsing Jien Kung, Christopher P. Evans

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The hematogenous metastatic spread of prostate cancer is preferentially to bone and can result in significant patient morbidity. Although these metastatic lesions are typically osteoblastic, bone resorption is believed to have a prerequisite role in their development. Src kinase has been identified to contribute to prostate cancer tumor growth and metastasis. In addition, Src is also essential in bone metabolism, especially in bone resorption. We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer. We found that saracatinib inhibited PC-3 cell growth and invasion in a dose-dependent manner. Phosphorylation of Src, focal adhesion kinase, and P38 kinases was inhibited by saracatinib at the submicromolar range. Saracatinib also inhibited the expression and secretion of invasion-related molecules interlukin-8, urokinase-type plasminogen activator, and matrix metalloprotease-9. Receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and signaling were inhibited by saracatinib in both macrophages and PC-3 cells. In in vivo studies, control mice developed more severe osteolytic lesions compared with the treatment group. Immunohistochemical and biochemical assays of bone metabolites confirmed that saracatinib preserved bone architecture in the presence of prostate cancer tumor cells. In summary, we have shown the inhibition of PC3 cell growth and invasion by saracatinib. Src inhibition also blocked the RANKL stimulatory pathway in osteoclasts and PC3 cells. The inhibition of Src thus targets multiple sites involved in prostate cancer bone metastasis, which may offer a therapeutic advantage in treating advanced prostate cancer.

Original languageEnglish
Pages (from-to)1629-1637
Number of pages9
JournalMolecular Cancer Therapeutics
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2010
Externally publishedYes

Fingerprint

src-Family Kinases
Bone and Bones
Prostatic Neoplasms
Osteoclasts
Bone Resorption
Growth
Neoplasms
Neoplasm Metastasis
Focal Adhesion Protein-Tyrosine Kinases
Bone Neoplasms
saracatinib
Urokinase-Type Plasminogen Activator
Metalloproteases
Osteogenesis
Phosphotransferases
Macrophages
Phosphorylation
Ligands
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. / Yang, Joy C.; Bai, Lanfang; Yap, Stanley; Gao, Allen C.; Kung, Hsing Jien; Evans, Christopher P.

In: Molecular Cancer Therapeutics, Vol. 9, No. 6, 01.06.2010, p. 1629-1637.

Research output: Contribution to journalArticle

Yang, Joy C. ; Bai, Lanfang ; Yap, Stanley ; Gao, Allen C. ; Kung, Hsing Jien ; Evans, Christopher P. / Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 6. pp. 1629-1637.
@article{069278ef6e4a4cee9336e0d2eaefb421,
title = "Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model",
abstract = "The hematogenous metastatic spread of prostate cancer is preferentially to bone and can result in significant patient morbidity. Although these metastatic lesions are typically osteoblastic, bone resorption is believed to have a prerequisite role in their development. Src kinase has been identified to contribute to prostate cancer tumor growth and metastasis. In addition, Src is also essential in bone metabolism, especially in bone resorption. We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer. We found that saracatinib inhibited PC-3 cell growth and invasion in a dose-dependent manner. Phosphorylation of Src, focal adhesion kinase, and P38 kinases was inhibited by saracatinib at the submicromolar range. Saracatinib also inhibited the expression and secretion of invasion-related molecules interlukin-8, urokinase-type plasminogen activator, and matrix metalloprotease-9. Receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and signaling were inhibited by saracatinib in both macrophages and PC-3 cells. In in vivo studies, control mice developed more severe osteolytic lesions compared with the treatment group. Immunohistochemical and biochemical assays of bone metabolites confirmed that saracatinib preserved bone architecture in the presence of prostate cancer tumor cells. In summary, we have shown the inhibition of PC3 cell growth and invasion by saracatinib. Src inhibition also blocked the RANKL stimulatory pathway in osteoclasts and PC3 cells. The inhibition of Src thus targets multiple sites involved in prostate cancer bone metastasis, which may offer a therapeutic advantage in treating advanced prostate cancer.",
author = "Yang, {Joy C.} and Lanfang Bai and Stanley Yap and Gao, {Allen C.} and Kung, {Hsing Jien} and Evans, {Christopher P.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-09-1058",
language = "English",
volume = "9",
pages = "1629--1637",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

AU - Yang, Joy C.

AU - Bai, Lanfang

AU - Yap, Stanley

AU - Gao, Allen C.

AU - Kung, Hsing Jien

AU - Evans, Christopher P.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - The hematogenous metastatic spread of prostate cancer is preferentially to bone and can result in significant patient morbidity. Although these metastatic lesions are typically osteoblastic, bone resorption is believed to have a prerequisite role in their development. Src kinase has been identified to contribute to prostate cancer tumor growth and metastasis. In addition, Src is also essential in bone metabolism, especially in bone resorption. We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer. We found that saracatinib inhibited PC-3 cell growth and invasion in a dose-dependent manner. Phosphorylation of Src, focal adhesion kinase, and P38 kinases was inhibited by saracatinib at the submicromolar range. Saracatinib also inhibited the expression and secretion of invasion-related molecules interlukin-8, urokinase-type plasminogen activator, and matrix metalloprotease-9. Receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and signaling were inhibited by saracatinib in both macrophages and PC-3 cells. In in vivo studies, control mice developed more severe osteolytic lesions compared with the treatment group. Immunohistochemical and biochemical assays of bone metabolites confirmed that saracatinib preserved bone architecture in the presence of prostate cancer tumor cells. In summary, we have shown the inhibition of PC3 cell growth and invasion by saracatinib. Src inhibition also blocked the RANKL stimulatory pathway in osteoclasts and PC3 cells. The inhibition of Src thus targets multiple sites involved in prostate cancer bone metastasis, which may offer a therapeutic advantage in treating advanced prostate cancer.

AB - The hematogenous metastatic spread of prostate cancer is preferentially to bone and can result in significant patient morbidity. Although these metastatic lesions are typically osteoblastic, bone resorption is believed to have a prerequisite role in their development. Src kinase has been identified to contribute to prostate cancer tumor growth and metastasis. In addition, Src is also essential in bone metabolism, especially in bone resorption. We hypothesized that inhibiting Src activity with the specific Src family kinase inhibitor saracatinib (AZD0530) would inhibit tumor cell growth and osteoclast differentiation in the tumor-bone interface, thus providing a new approach for advanced prostate cancer. We found that saracatinib inhibited PC-3 cell growth and invasion in a dose-dependent manner. Phosphorylation of Src, focal adhesion kinase, and P38 kinases was inhibited by saracatinib at the submicromolar range. Saracatinib also inhibited the expression and secretion of invasion-related molecules interlukin-8, urokinase-type plasminogen activator, and matrix metalloprotease-9. Receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and signaling were inhibited by saracatinib in both macrophages and PC-3 cells. In in vivo studies, control mice developed more severe osteolytic lesions compared with the treatment group. Immunohistochemical and biochemical assays of bone metabolites confirmed that saracatinib preserved bone architecture in the presence of prostate cancer tumor cells. In summary, we have shown the inhibition of PC3 cell growth and invasion by saracatinib. Src inhibition also blocked the RANKL stimulatory pathway in osteoclasts and PC3 cells. The inhibition of Src thus targets multiple sites involved in prostate cancer bone metastasis, which may offer a therapeutic advantage in treating advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=77953455677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953455677&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-1058

DO - 10.1158/1535-7163.MCT-09-1058

M3 - Article

VL - 9

SP - 1629

EP - 1637

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -